....In connection with the Amendment, if Resverlogix and EVERSANA have not launched a product by July 1, 2022, Resverlogix will make monthly payments to EVERSANA, commencing in July 2022, equal to 50% of the deferred fees for the corresponding month twelve months prior....
Just a guess, but given the quote below from the press release, perhaps the above will be pushed out a year or so, similiar to the debenture extension.
...."We’re pleased to support this important evolution of apabetalone and Resverlogix in its Phase 3 CORAL study," said Kevin McDermott, Resverlogix Chief Commercial Officer, EVERSANA. "The EVERSANA COMPLETE Commercialization model is built to support customer needs by offering flexibility to quickly adapt development and launch strategies to meet market demands."....
(my bolding)
